AllianceBernstein’s 4D Molecular Therapeutics FDMT Stock Holding History

AllianceBernstein’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$519K	Buy	55,740 +640	+1%	+$6.24K	﹤0.01%	2688
2026 Q1	$413K	Hold	55,100	–	–	﹤0.01%	2733
2025 Q4	$413K	Sell	55,100 -10,190	-16%	-$103K	﹤0.01%	2752
2025 Q3	$567K	Hold	65,290	–	–	﹤0.01%	2616
2025 Q2	$242K	Buy	65,290 +9,420	+17%	+$33.1K	﹤0.01%	3004
2025 Q1	$180K	Hold	55,870	–	–	﹤0.01%	2949
2024 Q4	$311K	Hold	55,870	–	–	﹤0.01%	2849
2024 Q3	$604K	Hold	55,870	–	–	﹤0.01%	2570
2024 Q2	$1.17M	Buy	55,870 +19,320	+53%	+$485K	﹤0.01%	2217
2024 Q1	$1.16M	Buy	36,550 +6,380	+21%	+$163K	﹤0.01%	2178
2023 Q4	$611K	Sell	30,170 -53,100	-64%	-$699K	﹤0.01%	2511
2023 Q3	$1.06M	Sell	83,270 -5,370	-6%	-$89.8K	﹤0.01%	2206
2023 Q2	$1.6M	Buy	88,640 +71,540	+418%	+$1.32M	﹤0.01%	2032
2023 Q1	$294K	Hold	17,100	–	–	﹤0.01%	2777
2022 Q4	$380K	Buy	+17,100	New	+$264K	﹤0.01%	2775

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

AllianceBernstein's FDMT Position: Q2 2026 in Review

AllianceBernstein increased its 4D Molecular Therapeutics (FDMT) stake by 1.2% in Q2 2026, buying an estimated $6.24K and bringing the position to 55,740 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #2688.

AllianceBernstein first reported a position in FDMT in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.6M in Q2 2023. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

AllianceBernstein held 55,740 shares of 4D Molecular Therapeutics worth $519K as of Q2 2026.
AllianceBernstein bought 640 4D Molecular Therapeutics shares in Q2 2026, an estimated $6.24K.
4D Molecular Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2688 holding.
AllianceBernstein first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 15 quarters since.
AllianceBernstein's 4D Molecular Therapeutics position peaked at $1.6M in Q2 2023.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.